Sagent Pharmaceuticals, Inc. Announces the Launch of Ondansetron Injection, USP  
9/10/2012 9:07:08 AM

SCHAUMBURG, Ill., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ondansetron Injection, USP, an antiemetic, in two latex-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Ondansetron Injection, USP approximated $49 million. As with all products in Sagent's portfolio, Ondansetron features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.